Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Methotrexate polyglutamate concentrations and gene polymorphisms in rheumatic diseases in southern Fujian
ChiCTR1800016154Phase 4Not yet recruiting
- Sponsor
- The Second Affiliated Hospital of Fujian Medical University
- Start
- Jun 2018
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of methotrexate in rheumatism, rheumatoid arthritis (RA), ankylosing spondylitis (AS) and 1 more, sponsored by The Second Affiliated Hospital of Fujian Medical University. Primary endpoints: Erythrocyte methotrexate polyglutamate concentration, MDR1 polymorphism and 4 more. Planned start Jun 2018; status: not yet recruiting.
02
Drugs
methotrexate
03
Conditions
rheumatismrheumatoid arthritis (RA)ankylosing spondylitis (AS)systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on ChiCTR1800016154.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1800016154.